Taking it

T-20 (enfuvirtide, Fuzeon) needs to be injected subcutaneously, as in oral form it is destroyed by stomach acids. The recommended adult dosage is 90mg injected twice daily. The injections must be prepared daily, but both daily doses can be constituted at the same time. This takes about 50 minutes. Patients are provided with a carton containing vials of T-20 powder, water to dissolve the powder, as well as syringes and alcohol swabs. Detailed, step-by-step instructions on how to inject T-20 are included in the carton.

 The drug has to be reconstituted from a powder, in a five-step process:

  1. Users must use a disposable syringe to draw up sterile water from the vial.
  2. The sterile water is then injected slowly into another vial containing the freeze-dried powder.
  3. The vial is rocked slowly from side to side in order to dissolve the powder and then left for up to 45 minutes.
  4. When the powder has dissolved, the vial’s lid must be pierced with a second sterile needle and the liquid drawn up into the syringe.
  5. The liquid is then injected beneath the skin of the abdomen, arm, or leg.

A vial of dissolved powder can be prepared at the beginning of the day for use in the evening or in the evening for use the following morning. Once constituted, the medication should be kept in the refrigerator until it is used. Although the drug should be taken every twelve hours, pharmacokinetic studies suggest that a delay of up to four hours is unlikely to be too serious.

Roche developed the Biojector, a needle-free device that had the potential to lessen injection site reactions, but which could also cause nerve pain in some persons lasting up to six months.1 In October 2007, Roche withdrew its marketing application to the US FDA for approval, citing the amount of time it would have taken to generate additional safety data. Patients in the US who are currently using the B2000 to administer T-20 will be allowed to continue to use the B2000 to take the drug. The company will continue to explore other options for administering T-20.

References

  1. Gottlieb M et al. Needle-free administration of enfuvirtide significantly reduces incidence of painful injection site reactions: results from a single blind, randomized, controlled study. Forty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, abstract H-1905b, 2006
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.